Skip to main content

Advertisement

Table 2 Kinetic clearance parameters for patients

From: Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer

Patient # 1 2 3 4 5 6 7 8 9 10 Mean SD
WB A 1 0.67 0.89 0.86 0.70 0.80 0.50 0.67 0.28 0.71 0.67 0.67 0.18
WB a 1 (h-1) 0.29 0.24 0.38 1.11 0.45 2.10 0.53 0.89 0.52 0.98 0.75 0.56
WB A 2 0.33 0.11 0.14 0.30 0.20 0.50 0.33 0.72 0.29 0.33 0.33 0.18
WB a 2 (h-1) 0.06 0.02 0.03 0.06 0.05 0.09 0.08 0.08 0.06 0.10 0.06 0.03
Blood A 1 (%/l) 5.9 18.7 5.7 2.2 5.1 7.1 3.5 2.5 3.2 2.6 5.7 4.9
Blood a 1 (h-1) 5.1 6.5 5.8 0.8 1.3 5.6 0.7 1.4 0.8 1.0 2.9 2.5
Blood A 2 (%/l) 1.3 2.48 1.2 0.38 0.68 0.88 0.88 1.07 0.74 0.61 1.01 0.58
Blood a 2 (h-1) 0.12 0.12 0.13 0.08 0.07 0.45 0.07 0.10 0.09 0.12 0.13 0.11
Gut fraction 0.031 0.030 0.027 0.049 0.037 0.033 0.030 0.050 0.047 0.016 0.03 0.02
  1. Whole-body and blood clearance data were fitted to bi-exponential functions viz A(t) = A 1 exp(-a 1 t) + A 2 exp(-a 2 t), where t is time in hour. Gut fraction is the estimated fraction of 124I-IAZGP present in the intestine at (nominally) 24 h after administration.